A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke

NCT07205328 · tracked via the Priya Life Science China tracker

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Phase

Phase 2

Started

2025-10

Last updated

2025-10-03

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

MT200605MT200605MT200605Placebo

MT200605: MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

Placebo: The placebo does not contain any active ingredients.

Study summary

MT200605 is an agonist of the receptor tyrosine kinase B (TrkB). It exerts brain-derived neurotrophic factor (BDNF)-like effects, protecting the structure and function of neural tissues in the brain. Simultaneously, it enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.

MT200605 is anticipated to confer pharmacological benefits including the reduction of neuronal apoptosis, antioxidant/free radical scavenging activity, anti-inflammatory effects, modulation of neuronal excitability, and amelioration of cerebral ischemic injury in patients with ischemic stroke.

This Phase II exploratory study will be conducted across 32 research centers in China. It plans to enroll 360 patients diagnosed with acute ischemic stroke within 24 hours of onset. Subjects will be randomized to receive either a high, medium, or low dose of MT200605 or a placebo, in addition to standard medical care. The primary efficacy endpoint is the proportion of subjects achieving a modified Rankin Scale (mRS) score of ≤1 at 3 months post-stroke. Secondary efficacy endpoints include the reduction in the National Institutes of Health Stroke Scale (NIHSS) score from baseline at day 14, among others.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Age between 18 and 80 years old (inclusive), male or female ; 2. Diagnosed with ischemic stroke according to the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023"; 3. The time from the onset of the disease to the expected administration of the investigational drug will be within 24 hours., including patients who have not received reperfusion therapy or those have received intravenous thrombolysis treatment; 4. The NIHSS score at admission is between 6 and 25 (inclusive), and the sum of the scores for the 5th（upper limb movement） and the 6th（ lower limb movement） is ≥ 2 points; 5. The mRS score before this onset of stroke is 0 to 1, and there are no obvious clinical symptoms and signs that affect the NIHSS score; 6. Able to understand and cooperate with the process of this study, and voluntarily sign the informed consent. Exclusion Criteria: 1. Imaging examinations show concurrent intracranial hemorrhagic disorders: such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc. If there is minor bleeding, it could be determined based on the researcher's judgment whether the subject was suitable for inclusion; 2. After the onset of the disease, obvious consciousness disorders occurre, and the score of the NIHSS item for the 1a level of consciousness is \>1 point; 3. Transient ischemic attack (TIA); 4. This acute ischemic stroke requires endovascular treatment (including intravenous thrombolysis, mechanical thrombectomy, angioplasty); 5. At the time of admission, already known severe active kidney disease, renal insufficiency; or serum creatinine \> 1.5 × ULN; 6. Severe active liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis, etc.; or ALT or AST \> 2.0 × ULN;

Primary outcome measure(s)

Modified Rankin Scale（mRS） — 90 ± 5 days after the onset of stroke

Trial sites (1)

Facility	City	Region	Status
BeiJing Tiantan Hospital	Beijing	Beijing Municipality	Recruiting

More Shaanxi Micot Pharmaceutical Technology Co., Ltd. trials in China

Phase I Study of MT1011 Injection in Healthy Subjects Recruiting

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis Recruiting

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism Recruiting

Other trials for the same condition

Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke Starting soon

Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management Recruiting

Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke Recruiting

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke Recruiting

The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07205328 on ClinicalTrials.gov ↗ ← All trials in China